Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced receipt of revised regulatory ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Management expects significant contributions from U.S. incretin class growth and international Mounjaro launches. Earnings per share (EPS) for 2025 are projected at $22.50 to $24.00. Management ...

One observation I would make about the GLP-1 / incretin mimetic class of drugs is that they are clearly difficult to develop. Lilly and Novo have been working with this drug class for >30 years ...